# Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With MDD

> **NCT05137197** · NA · UNKNOWN · sponsor: **Taliaz Ltd.** · enrollment: 354 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DEVICE:** Predictix Genetics Antidepressant

## Key facts

- **NCT ID:** NCT05137197
- **Lead sponsor:** Taliaz Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-04
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05137197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05137197, "Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With MDD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05137197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*